About
Neobiosis develops and manufactures perinatal products from birth tissues like amniotic fluid, placenta, and umbilical cord. These products contain cells, extracellular vesicles, and matrix to support regenerative processes. The company operates as a CDMO, providing product development and manufacturing services for research and clinical trials under CGMP standards.
Their approach draws from heterochronic parabiosis, where regenerative factors from young tissues aid repair in older ones. They extract growth factors and compounds from perinatal materials to empower clinical research on tissue regeneration. Owned by physicians and scientists, Neobiosis focuses on measured partnerships to advance regenerative medicine.
Products like ViXome, derived from amniotic fluid, target applications in regeneration and specific conditions. Processing occurs in FDA-registered cleanrooms, with R&D at a leading biotech incubator. This integrated method supports precise delivery of regenerative agents.
Sources
Longevity Contribution
- Proprietary technology to extract cells, EVs, and matrix from perinatal birth tissues.
- CDMO services with CGMP-compliant cleanrooms and R&D at University of Florida's top biotech incubator.
- Foundation in heterochronic parabiosis research for transferable regeneration.
- Physician and scientist ownership focused on clinical trial preparation.
